All articles tagged with #marty makary
Kyle Diamantas, formerly FDA deputy for food, becomes acting FDA commissioner after Marty Makary’s resignation, guiding food safety policy and dietary guidelines during an interim leadership phase; his past defense of Abbott’s infant formula and ties to Trump circles are noted, but he’s seen as a non-controversial placeholder while a permanent appointee is sought.
FDA Commissioner Marty Makary resigned amid months of internal turmoil at the agency, with a plan to replace him approved by the White House. Kyle Diamantas will serve as acting leader, as the shake-up at the Department of Health and Human Services continues to unfold.
FDA Commissioner Marty Makary resigns under mounting pressure over the administration’s flavored e-cigarette approval, with acting commissioner Kyle Diamantas set to take over as the agency grapples with staff shortages, industry pushback, and a looming search for a permanent replacement who must balance political goals with federal law.
Dr. Marty Makary is leaving as FDA commissioner, the fourth high-profile Trump-era departure this year; his tenure coincided with the FDA authorizing fruit-flavored vapes for adults and GOP pressure over a promised safety review of the abortion drug mifepristone, with reports that Makary asked officials to delay the review until after the midterms.
FDA Commissioner Marty Makary resigns after 13 months amid leadership churn and policy clashes; Kyle Diamantas will serve as acting commissioner, with the White House sign-off and HHS Secretary Robert F. Kennedy Jr. driving the transition amid criticism from lawmakers and industry.
Trump is reportedly planning to fire FDA Commissioner Marty Makary, a Johns Hopkins surgeon who was confirmed to lead the agency in March 2025, citing clashes with the administration and officials. NBC News, The New York Times, The Wall Street Journal and The Washington Post all attributed the plan to anonymous sources. Makary’s tenure has seen significant staff departures and criticism from health groups and industry, and the plan could change if Trump reverses course.
President Trump is reportedly planning to fire FDA Commissioner Marty Makary, a move that sources say isn’t final yet; if enacted, it would heighten leadership vacancies at the FDA amid a year of controversy over vaping, vaccines, and regulatory decisions.
The White House plans to replace FDA Commissioner Marty Makary after months of agency turmoil and criticism over drug approvals and vaccine policies; while broader FDA changes are being considered, officials have not named an acting leader and did not comment.
President Donald Trump allegedly upbraided FDA Commissioner Marty Makary for not moving quickly enough to approve flavored vapes, putting him on 'thin ice' as advisers weigh the administration’s vaping agenda; Makary had previously balked at approving certain fruit flavors and discussed pivoting away from a hard-line stance, though it’s unclear if he’ll change course. If fired, he’d join other high-profile ousters; flavored cartridge vapes have been FDA-banned since 2020 and many states have expanded bans.
President Donald Trump pressed FDA Commissioner Marty Makary to move faster on approving flavored vaping products, according to WSJ sources. Advisers reportedly described Makary as a hurdle to Trump’s push to “save” vaping, amid years of FDA caution that has permitted only about 41 vape products so far (all tobacco or menthol flavors) and a stringent evidentiary burden for flavors that appeal to youth. It remains unclear whether Makary will change course.
Dr. Vinay Prasad, a divisive FDA vaccine regulator who overruled career scientists and pressed a crackdown on a biotech firm, is resigning at the end of April after a turbulent tenure that included a brief dismissal sparked by Laura Loomer’s attack and a later reinstatement urged by FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr.
The FDA, led by Dr. Marty Makary in a White House event with President Trump, proposed a new framework to speed approvals for therapies targeting rare diseases.
FDA officials say a single pivotal trial will be the default standard for drug approvals, a policy shift outlined in an NEJM perspective by Marty Makary and Vinay Prasad.
Marty Makary, the new FDA commissioner, has made a series of bold announcements and media appearances in his first 100 days, including a proposal to make public the complete response letters sent to companies regarding drug approvals. While this could lead to positive changes, there are concerns that some of his initiatives may overlook the FDA's traditional methods and risk undermining its effective functioning, with uncertain outcomes.
The FDA is experiencing a significant loss of experienced staff due to low morale, political interference, and staffing cuts, which threatens its ability to effectively regulate food, drugs, and medical devices under new Commissioner Marty Makary.